Table 9.
ED50s (95% confidence limits; mg/kg) of the PDE10AIs for interactions with RO-4-1284-induced behavior related to their ED50 for inhibition of apomorphine-induced behavior
| JNJ-42314415 | PQ-10 | MP-10 | ||||
|---|---|---|---|---|---|---|
| Compound | ED50 (95% CL) | Ratio1 | ED50 (95% CL) | Ratio1 | ED50 (95% CL) | Ratio1 |
| Apomorphine test | ||||||
| Inhibition of agitation | 0.95 | [1.0] | 3.5 | [1.0] | 0.88 | [1.0] |
| RO-4-1284 interaction | ||||||
| Reversal of sedation | 0.59 (0.44–0.80) | [0.62] | 3.6 (2.89–4.3) | [1.0] | 0.68 (0.50–0.91) | [0.77] |
| Reversal of catalepsy | 1.03 (0.69–1.54) | [1.1] | 4.7 (2.91–7.6) | [1.3] | 0.78 (0.57–1.05) | [0.89] |
| Induction of excitation | 2.05 (1.37–3.1) | [2.2] | 14.2 (8.8–22.8) | [4.0] | 3.1 (1.91–5.0) | [3.5] |
Listed are ED50s obtained at time of peak effect together with the ratio over the ED50 for apomorphine antagonism. PDE10AI, phosphodiesterase 10A inhibitor
1
The ratio over the corresponding ED50 for apomorphine antagonism is listed between square brackets.